Thoracic Fluid Content as an Outcome Predictor in Intensive Care Unit

NCT ID: NCT07100821

Last Updated: 2025-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hemodynamic monitoring is measuring and monitoring the factors that influence the force and flow of the blood. It is an important aspect of patients care in operating rooms and critical care units. It aims to guide medical management so as to prevent or treat organ failure and improve the outcomes of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hemodynamic monitoring is measuring and monitoring the factors that influence the force and flow of the blood. It is an important aspect of patients care in operating rooms and critical care units. It aims to guide medical management so as to prevent or treat organ failure and improve the outcomes of patients. This monitoring itself includes several different techniques and may range from invasive to less and even non-invasive techniques.

Critically ill patients are often hemodynamically unstable (or at risk of becoming unstable) owing to hypervolemia, cardiac dysfunction or alterations of vasomotor function, leading to organ dysfunction, deterioration into multi-organ failure and eventually death range from 15% to 25% of patients admitted to intensive care units.

Impedance cardiography (ICG) and Electrical Cardiometry (EC) are recently developed technologies to measure thoracic fluid content (TFC), cardiac output (CO) and other hemodynamic parameters. Both ICG and EC derive CO from measurements of Thoracic Electrical Bioimpedance (TEB).

One of the parameters examined by electrical cardiometry is thoracic fluid content(TFC) ,which is inversely associated with the patient's transthoracic electrical bioimpedance, and reflects the total (intravascular and extravascular) fluid volume contained in the chest cavity. A study concluded that electrical cardiometry monitoring indicated new possibility to anticipate prognosis of pneumonia patient. Increased thoracic fluid content value would relate to worse outcome of the patient like mortality and intensive care unit admission. Electrical cardiometry monitoring allows real-time measurements of thoracic fluid content without restraining the patient or invasive catheters.

In ARDS patients with cardiac comorbidities, TFC can distinguish between non-cardiogenic and cardiogenic pulmonary edema. In addition, TFC is helpful in the differential diagnosis of the mechanisms of respiratory failure. Thus, recently it was shown that TFC was greater in ARDS than in patients with atelectasis or pleural effusion. Therefore, depending on the TFC value, we can provide different therapeutic interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thoracic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients indicated for admission to respiratory critical care unit of chest medicine department

130 patients \>18 years old were enrolled during the period from December 2023 to December 2024

Hemodynamic parameters was measured by using electric cardiometry (ICON)

Intervention Type DIAGNOSTIC_TEST

Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemodynamic parameters was measured by using electric cardiometry (ICON)

Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years.
* Patients indicated for admission to respiratory critical care unit of chest medicine department at Mansoura University Hospitals whatever the indication was.

Exclusion Criteria

* Patients with malignancy either primary or metastatic lung cancer.
* Advanced chronic pulmonary fibrosis.
* Pleural and or pericardial effusions.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Abd Elmoniem Mohamed

Lecturer faculty of medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed AbdElmoniem

Role: PRINCIPAL_INVESTIGATOR

Lecturer of chest medicine faculty of medicine Mansoura university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mohamed AbdElmoniem

Al Mansurah, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS.19.12.354

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.